Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy
Open Access
- 8 January 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1432758
Abstract
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs (VIPomas) not responsive to any other therapies who achieved symptomatic control and a significant decrease in serum VIP levels with PRRT during their hospital stay. Two patients with VIPomas were admitted to the hospital with multiple prior hospital admissions after going through multiple lines of therapy. The first patient was a 47-year-old woman with a grade 2 pancreatic VIP-secreting NET. She was treated with somatostatin analogs and chemotherapy; however, she experienced recurrent symptoms and complications leading to two hospital admissions, one of which included an intensive care unit (ICU) admission. The patient was treated with lutetium-177 DOTATATE while in the hospital, which led to the resolution of the symptoms and a marked decline in serum VIP levels, and she was able to be discharged from the hospital after 147 days of hospitalization (16 days after PRRT). The second patient was a 27-year-old man who was diagnosed with a well-differentiated grade 3 pancreatic VIPoma. He also suffered from severe diarrhea and was not responsive to any form of therapy, including liver embolization. He was also treated with PRRT on admission, which led to immediate resolution of his symptoms and a decrease in tumor markers. In conclusion, 177Lu-DOTATATE is an effective treatment for highly symptomatic VIPoma. Inpatient administration of PRRT can rapidly reduce diarrhea and fluid and electrolyte complications of VIP secretion and may shorten hospital stays.Keywords
This publication has 23 references indexed in Scilit:
- Efficacy of treatments for VIPoma: A GTE multicentric seriesPancreatology, 2021
- Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategiesThe Lancet Diabetes & Endocrinology, 2018
- Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30European Journal of Nuclear Medicine and Molecular Imaging, 2017
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsNew England Journal of Medicine, 2017
- Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survivalAnnals of Oncology, 2008
- Vasoactive intestinal peptide: cardiovascular effectsCardiovascular Research, 2001
- Vasoactive intestinal polypeptide secreting islet cell tumors: A 15-year experience and review of the literatureSurgery, 1998
- Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemiaThe American Journal of Medicine, 1958